Dyslexia Treatment Market Research Report—Global Forecast till 2027

Dyslexia Treatment Market: Information by Type of Dyslexia (Phonological Dyslexia, Surface Dyslexia, Other), By Treatment & Diagnosis (Treatment, Tools, Diagnosis) and By End-User (Specialty Center, Home Care, Clinics, Others) – Forecast to 2027

ID: MRFR/HC/6890-CR | March 2022 | Region: Global | 169 Pages         

Dyslexia Treatment Market Speak to Analyst Request a Free Sample

Dyslexia Treatment Market

Dyslexia Treatment Market size is projected to be worth USD 38,514.67 million by 2027, registering a CAGR of 7.10 % during the forecast period 2021 - 2027

By Type of Dyslexia Phonological Dyslexia Surface Dyslexia Other
By Treatment & Diagnosis Treatment Tools Diagnosis
By End-User Specialty Center Home Care Clinics Others
Key Players
Companies Profiled   Pfizer    Inc. (US)   Speechify Inc. (US)   Jubilant Pharma Limited (Singapore)   Lingit AS (Norway)   Soli (UK)   Novartis AG (Switzerland)   Lyfta (UK)   GlaxoSmithKline (UK)   Teva Pharmaceutical Industries Ltd (Israel)   Eli Lilly & Company (US)
Market Driving Forces   Increasing prevalence of Dyslexia   Increasing app development activities to treat dyslexia
Request a Free Sample

Dyslexia Treatment Market Forecast

Global dyslexia treatment market size is projected to be worth USD 38,514.67 million by 2027, registering a CAGR of 7.10 % during the forecast period (2021 - 2027), The market was valued at USD 23,682.69 million in 2020.

Market Overview:

Dyslexia is a medical condition where the patient faces difficulty in writing, reading, and remembering unfamiliar or difficult words. It is a neurological learning disorder that can be found in various regions of people. Dyslexia can be treated at an early age of the children by employing special teaching techniques.  The growth of the global dyslexia treatment market is expected to be driven by the increasing prevalence of dyslexia and increasing app development activities to treat dyslexia and among others. However, lack of awareness about dyslexia, its symptoms, and underdiagnosis is a restraining factor for the dyslexia treatment market. On the other hand, collaboration with schools, colleges, and non-profit organizations provides lucrative opportunities for players operating in the global dyslexia treatment market.

COVID-19 Analysis:

The COVID-19 pandemic causes a massive shift in the distribution of healthcare. The impact of COVID-19 was evaluated by understanding various case studies and inferring the results of research carried out globally. Neuropsychological tests and an ad hoc questionnaire to explore reading skills found out between 59 to 63% of children with dyslexia did not reach the average expected increase of reading skills. According to their parents, social isolation and school closure have impacted the reading abilities of children to a greater extent. The school closures in various countries have impacted children with learning disabilities and thereby increasing the need to focus on better options available to address challenges. Lack of special attention for children with learning disabilities during a pandemic is expected to increase the facilities required to address the needs of dyslexic children. This large demand created for educational needs is expected to pave way for manufacturers to develop products such as software to capitalize on opportunities generated due to COVID-19.

Market Dynamics:

Market Drivers

  • Increasing prevalence of Dyslexia

Worldwide statistics emphasize that one in ten people will have dyslexia. Somewhere between 25-40% of children with dyslexia also have attention deficit hyperactivity disorder (ADHD) and conversely, approximately 25% of children with ADHD also have dyslexia. A whitepaper titled “The Economic Impact of Dyslexia on California” published by Boston Consulting Group (US) in July 2020 was estimated to cost California approximately USD 12 billion in 2020 and USD 1 trillion over the next 60 years.

  • Similarly, according to Dystech (Australia), a science-based company publishing scientific research papers, in Australia in 2018, only 15% of students failed to complete 12 years of school whereas 35% of dyslexic students drop out of school. Thus, an increase in the level of awareness in developing regions about dyslexia is expected to increase the diagnosis rate during the forecast period.

  • Increasing app development activities to treat dyslexia

Market Restraints

  • Lack of awareness about dyslexia, its symptoms, and underdiagnosis

Students with dyslexia may need specialized instruction and special arrangements for tests, extra time for tests, homework, and taking notes in class. Some of the strategies like listening to audiobooks as an alternative to reading, typing on a computer or tablet instead of writing, and using apps that can make learning fun by turning decoding into a game can be employed for dyslexics. A group of researchers carried out a cross-sectional study in nine Italian Regions: two located in Northern Italy, three in Central Italy, and four in Southern Italy during 2019. The researchers recruited 11,094 children aged 8–10 years including only children who received parents’ consent to participate. The prevalence of dyslexia in the whole sample was 3.5%, with little differences between Northern, Central, and Southern Italy. In almost two out of three children with dyslexia, the disorder had not been previously diagnosed.

  • Not having an early diagnosis of dyslexia

Market Opportunities

  • Collaboration with schools, colleges, and nonprofit organizations

A large number of schools are focused on catering education for kids with learning difficulties. Similarly, non-profit organizations fund educational and financial resources to people with special needs. For instance, The Baily Thomas Charitable Fund provides funding to registered charities working with children or adults with severe learning difficulties and Autism. Similarly, “Follow your Dreams” helps young people with learning difficulties reach their full potential whereas, Forbes Charitable Foundation supports small and medium-sized organizations for capital expenditure and some revenue expenditure in the form of grants. The developer of apps can collaborate with the government, curriculum designers, schools, and institutes of higher education to provide services and generate revenue. Similarly, app developers can attract investment and seed funding from charitable trusts to scale their operations.

Value Chain Analysis/Technology Analysis/Regulatory Implications

The global dyslexia treatment market is growing steadily and is expected to continue growing gradually at a significant rate in the near future. This is due to the growing contribution of existing players to make the service more effective. The value chain analysis for the dyslexia treatment market comprises four major components: customer acquisition, service customization, customer purchase support, customer fulfillment, and post-purchase support.

Segment Overview

The global dyslexia treatment market is segmented into type, treatment and diagnosis, end-user, and region.

By Type

  • Phonological dyslexia

Phonological dyslexia are the most common type of dyslexia where the patient suffers from extreme difficulty in reading. In this type of dyslexia, the patient is unable to process sounds and other auditory information. Here, the patients cannot break up words into smaller components, which results in guessing or mixing up phonemes, impacting reading efficiency. The risks of phonological dyslexia may include a family history of dyslexia, substance abuse, premature birth, and brain injury.

  • Surface Dyslexia

Surface dyslexia is also called visual or dyseidetic dyslexia. People with surface dyslexia generally fare well in phonemes awareness, unlike phonological dyslexia, but have trouble comprehending words that are spelled differently from their sounds. Some examples of such words include debt, island, weight, they, and yacht. Moreover, surface dyslexia is rare to develop genetically or inherently and is generally acquired in nature from stroke or brain injury in later stages of life.

  • Others

The other types of dyslexia include dysphonetic dyslexia, double deficit dyslexia, and attention dyslexia. In dysphonetic dyslexia, the patient is unable to read individual syllables or letters from words. Double deficit dyslexia can be referred to as the severe case of dyslexia wherein the patient suffers from phonological dyslexia as well as reduced naming speed. Attention dyslexia refers to patients who are suffering from Attention-Deficit/Hyperactivity Disorder (ADHD) as well as dyslexia. Studies show that 30% of those who have dyslexia suffer from ADHD as well.

By Treatment & Diagnosis

  • Treatment

There is no particular method of treating dyslexia, but with early detection and careful evaluation, the condition of dyslexia can be improved through personalized treatment options. Medications for dyslexia are mostly experimental and are prescribed case to case. E-readers and tablets can customize how words appear on the screen, which can be beneficial for people with dyslexia in reading comprehension. Recent studies, such as one done by Smithsonian Institute, have found that people with dyslexia showed better reading comprehension when reading from e-readers such as the Amazon Kindle products.

  • Diagnosis

Dyslexia is diagnosed clinically based on a synthesis of data from various sources, such as personal and family history, observations of speaking and reading, and reading and language tests. Accuracy, fluency, and understanding are all evaluated in reading assessments. This is done by psychologists, learning disability specialists, or diagnostic specialists.

By End-User

  • Specialty Center

Specialty centers are specialized settings for the treatment of mental health disorders. Specialty centers have gained demand in cases of dyslexia as it is observed that children suffering from dyslexia generally suffer from some other psychiatric disorder. According to a report published by Assiut University, Egypt in July 2020, in children diagnosed with dyslexia over 60% of them suffer from at least one other psychiatric disorder. Therefore, psychiatric institutions become essential to provide treatment and care for such co-morbid cases of dyslexia.

  • Home Care

In-home settings, the child experiences the safest environment, which is ideal for learning. Moreover, there are abundant facilities available to help improve reading capabilities at homes, such as apps, e-readers, virtual consulting sessions, and more.

  • Hospitals & Clinics

Hospitals & clinics are expected to hold a significant market share owing to the availability of medical experts like psychologists and neurologists and the accessibility of hospitals. Moreover, hospitals & clinics have access to specialized instruments such as EEG machines which can be used to correctly diagnose dyslexia and/or other related co-morbid disorders.

  • Others

Other end-users of the global dyslexia treatment & diagnosis market include special schools, rehabilitation centers, and pharmacies. Special schools are schools specific for dyslexic students where an environment that would boost their learning curve is created, with access to specialized educational techniques. Rehabilitation centers are in-patient treatment centers where the patient stays in the facility and receives treatment. Lastly, pharmacies provide access to medications utilized for the treatment of dyslexia.

Regional AnalysisGlobal Dyslexia treatment Market Share (%), By Region, 2020Global Dyslexia Treatment Market Share By Region 2020Source: MRFR Analysis

The global dyslexia treatment market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

North America:

The North America market is segmented into the US and Canada. North America accounted for the largest market share of 5.79% is due to the presence of developed healthcare infrastructure, favorable government policies, presence of major key companies headquarters in the region such as Jubilant Cadista (US) and Speechify (US), and high prevalence of dyslexia are driving the market in the region. For instance, according to the Dyslexia Center of Utah, one in five students, i.e., 15%-20% of the US population, have a learning-based disability, most commonly dyslexia. Furthermore, there are several not-for-profit organizations based in the region with a global presence. These organizations increase awareness regarding dyslexia and provide support to patients and their families. One such organization is the International Dyslexia Association (IDA), based in the US. IDA has over 40 branches along with 24 global partners. Additionally, the region houses a large number of special schools specifically for children with dyslexia.


Europe accounted for a sizable portion of the global dyslexia treatment & diagnosis market. Like North America, Europe also faces a high prevalence of dyslexia. According to an article published in December 2019 by The Institute of Entrepreneurship Development (iED), 15% of the European population suffers from dyslexia. Additionally, of the 15% affected by dyslexia, a large number of them suffer from other co-morbid disorders. Around 20-55% of people with dyslexia suffer from dyslexic, 20-40% from dyscalculia, and 10-20% from anxiety disorders. There are around 6 million residing in the UK itself. Hence, there is a high demand for quality treatment and diagnostics capabilities in the region.


Asia-Pacific is the fastest-growing regional market for the dyslexia treatment & diagnosis market as it is developing rapidly and has witnessed the emergence of many players. There is also a high prevalence of dyslexia driving the market growth. According to the Department of Biotechnology, in 2019, around 35 million children in India were suspected to be dyslexics. Additionally, counties in the Asia-Pacific regions have also developed their own dyslexia assessment tests to correctly identify the dyslexic population within the country and provide appropriate care.

Rest Of the World:

The rest of the world region showed restricted growth owing to a lack of mental health awareness and facilities. In Africa, one in ten people is suspected of having dyslexia. Organizations such as Dyslexia International are running initiatives to train teachers to handle students with dyslexia and facilities like e-learning and e-campus for dyslexic children in Africa. The region's market growth is majorly due to the presence of developed countries in the Middle East, especially the Gulf countries.

Competitive Landscape

The key players operating in the global dyslexia treatment market include Pfizer, Inc.  (US), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia). To expand their reach and optimize their operational costs, the major players have adopted the strategy of obtaining regulatory authorizations from government agencies for their products, as well as collaborative partnerships and new product launches to gain a substantial market share.

List of Key Companies Covered in this report:

  • Pfizer, Inc. (US)

  • Speechify Inc. (US)

  • Jubilant Pharma Limited (Singapore)

  • Lingit AS (Norway)

  • Soli (UK)

  • Novartis AG (Switzerland)

  • Lyfta (UK)

  • GlaxoSmithKline (UK)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Eli Lilly & Company (US)

  • RPG Life Sciences Ltd (India)

  • Hopalai D.O.O. (Slovenia)

Recent Developments

  • In April 2018, Lingit AS acquired Claro Software Ltd, a UK-based software company that offers multi-platform software for reading and writing support. With this acquisition, Lingit took its first international step in the industry.

  • In February 2018, Serdar Ferit (Co-CEO, Lyfta) conducted a Lyfta VR workshop in a London school. Based on the results of VR sessions at the workshop, the company decided to conduct a formal study about the effects of VR learning environments on reading for children with dyslexia.

  • In June 2017, The United States Food and Drug Administration (FDA) has approved the first generic version of Atomoxetine (Strattera) drug for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. The generic drug has been approved by the FDA to Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited for marketing atomoxetine in different strengths.

Report Overview:

The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.

Scope of the Report & Segmentation

Global Dyslexia Treatment Market, by Type

  • Phonological Dyslexia

  • Surface Dyslexia

  • Others

Global Dyslexia Treatment Market, by Application

  • Treatment

  • Diagnosis

Global Dyslexia Treatment Market, by End User

  • Specialty Center

  • Home Care

  • Hospitals & Clinics

  • Others

Global Dyslexia Treatment Market, by Region

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Western Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Report Scope:

Report Attribute/Metric Details
  Market Size   2027: USD 38,514.67 Million
  CAGR   7.10 %
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018-2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and Diagnosis, End User, and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   • Pfizer, Inc. (US) • Speechify Inc. (US) • Jubilant Pharma Limited (Singapore) • Lingit AS (Norway) • Soli (UK) • Novartis AG (Switzerland) • Lyfta (UK) • GlaxoSmithKline (UK) • Teva Pharmaceutical Industries Ltd (Israel) • Eli Lilly & Company (US) • RPG Life Sciences Ltd (India) • Hopalai D.O.O. (Slovenia)
  Key Market Opportunities   • Growing Collaboration with schools, colleges, and nonprofit organizations
  Key Market Drivers   • Increasing prevalence of Dyslexia • Increasing app development activities to treat dyslexia

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

dyslexia treatment market is projected grow at approximately7.10 % CAGR during the assessment period (2027).

The valuation of the dyslexia treatment market is estimated to increase to USD 38,514.7 MN by the end of 2027.

Growing awareness among populaces, increasing research in pharmaceutical and biotechnology industries, and growing government support for the development of therapeutic drugs to treat the symptoms caused by dyslexia are the major tailwinds pushing the growth of the global dyslexia treatment market.

North America holds the largest share in the dyslexia treatment market, followed by Europe and the Asia Pacific, respectively.

Pfizer Inc. (US), Jubilant Cadista (US), Micro Labs (India), Srikem Labs (India), Gangwal Chemicals Pvt. Ltd (India), Novartis AG (UK), RPG Life Sciences Ltd. Cian Healthcare Pvt. Ltd (India), Purdue Pharma (US), GlaxoSmithKline (UK), Eli Lilly & Company (US), Teva Pharmaceutical Industries Ltd (Israel), and Wallace Pharmaceuticals Ltd (US), are some of the major players operating in the global dyslexia treatment market.